Corporate Archives - Solentim

Corporate sciadseo March 27, 2019

Valitacell and Solentim secure €3.5m funding to optimise the development of new biologics and cell therapies

A consortium, consisting of Valitacell, Solentim and Microcoat, has been awarded €2.5million under the highly competitive H2020 Fast Track to Innovation (FTI) initiative, and a further €1million from other sources Solentim and Valitacell announce a total of €3.5m funding to produce an integrated platform to deposit, culture, profile and select optimal cells for the manufacture of life-saving …

Corporate sciadseo February 21, 2019

Valitacell and Solentim announce collaboration to accelerate discovery and development of biologic drugs and advanced cell therapies

21st February 2019: Valitacell, a biotechnology company transforming cell-based manufacturing, and Solentim, a global leader in cell line development instrumentation, today announced a new collaboration to enable earlier identification of biological candidates and to accelerate the development of breakthrough medicines. Valitacell’s novel in-line analytical profiling technologies and its data-driven/machine learning approach, together with Solentim’s …

advanced cell therapies cell-based manufacturing Collaboration development of breakthrough medicines

Corporate, Product sciadseo January 14, 2019

Solentim and ATUM announce technology collaboration to enable rapid, high expression, stable cell line development

NEWS – Bournemouth, UK – 14th January 2019: Solentim, a global leader in cell line development instrumentation, and bioengineering company ATUM, today announced a technology partnering and collaboration agreement. This agreement creates the most efficient cell line development solution for biotherapeutic drug developers yet, by integrating Solentim’s VIPS™ (verified in-situ plate seeding) hardware for isolating single …

Corporate matthews January 10, 2019

Solentim Strengthens Team | Claire Richards appointed Head of Biological Science

NEWS – Bournemouth, UK – 10th January 2019: Solentim, the innovator and leader in Cell Line Development instrumentation, is pleased to announce the appointment of Claire Richards as their new Head of Biological Science. Claire Richards began her career at the Wellcome Trust Sanger Institute/Cambridge University where she did her PhD in the Cancer Genome …

Corporate User 1 June 28, 2018

Solentim at the Palace

This week, members of Solentim’s management team enjoyed the privileged experience of visiting Buckingham Palace. The invitation to a private reception at the Palace followed Solentim’s success in winning two Queen’s Awards for Enterprise, announced in April, the first for Innovation and the second for International Trade. The reception was hosted by The Prince of …

Solentim report another record year

Sales Growth Soars to over 80% for 2016 NEWS – Bournemouth, UK – 12th January 2017: Solentim, the leader in Cell Line Development instrumentation, announce another record year of sales. “We have seen worldwide order values increase by over 80% year-on-year for calendar year 2016, and now nine out of the Top Ten Pharma have purchased …

Category: Corporate

Valitacell and Solentim secure €3.5m funding to optimise the development of new biologics and cell therapies

Valitacell and Solentim announce collaboration to accelerate discovery and development of biologic drugs and advanced cell therapies

Solentim and ATUM announce technology collaboration to enable rapid, high expression, stable cell line development

Solentim Strengthens Team | Claire Richards appointed Head of Biological Science

Solentim at the Palace

Solentim report another record year

Categories

Archives

Tags